NO330135B1 - Hydroksymatairesinol eller en geometrisk isomer eller en stereoisomer derav for anvendelse for forebygging av en kreftform og farmasoytisk preparat - Google Patents

Hydroksymatairesinol eller en geometrisk isomer eller en stereoisomer derav for anvendelse for forebygging av en kreftform og farmasoytisk preparat Download PDF

Info

Publication number: NO330135B1
Authority: NO; Norway
Prior art keywords: hmr; lignans; enterolactone; rats; hydroxymatairesinol
Prior art date: 1999-03-30

Application number

NO20014639A

Other languages

English (en)

Norwegian (no)

Other versions

NO20014639D0 (no

NO20014639L (no

Inventor

Christer Eckerman

Lauri Veikko Matti Kangas

Risto Santti

Markku Ahotupa

Sari Makela

Niina Saarinen

Anni Warri

Original Assignee

Hormos Medical Oy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-30

Filing date

2001-09-25

Publication date

2011-02-21

2001-09-25 Application filed by Hormos Medical Oy filed Critical Hormos Medical Oy

2001-09-25 Publication of NO20014639D0 publication Critical patent/NO20014639D0/no

2001-09-25 Publication of NO20014639L publication Critical patent/NO20014639L/no

2011-02-21 Publication of NO330135B1 publication Critical patent/NO330135B1/no

Links

UKHWOLNMBQSCLJ-BIENJYKASA-N hydroxymatairesinol Chemical compound C1=C(O)C(OC)=CC(C[C@H]2C(OC[C@@H]2[C@H](O)C=2C=C(OC)C(O)=CC=2)=O)=C1 UKHWOLNMBQSCLJ-BIENJYKASA-N 0.000 title description 86
YNOCUODOFOEIFZ-UHFFFAOYSA-N Hydroxymatairesinol Natural products C1=C(O)C(OC)=CC=C1CC1C(=O)OCC1C(O)C1=CC=C(OC)C(O)=C1 YNOCUODOFOEIFZ-UHFFFAOYSA-N 0.000 title description 84
230000002265 prevention Effects 0.000 title description 6
239000008194 pharmaceutical composition Substances 0.000 title 1
229930013686 lignan Natural products 0.000 description 55
235000009408 lignans Nutrition 0.000 description 55
150000005692 lignans Chemical class 0.000 description 53
241000700159 Rattus Species 0.000 description 34
206010028980 Neoplasm Diseases 0.000 description 28
HVDGDHBAMCBBLR-UHFFFAOYSA-N Enterolactone Natural products OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 description 25
HVDGDHBAMCBBLR-WMLDXEAASA-N enterolactone Chemical compound OC1=CC=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-WMLDXEAASA-N 0.000 description 25
230000001076 estrogenic effect Effects 0.000 description 25
238000012360 testing method Methods 0.000 description 19
210000004027 cell Anatomy 0.000 description 18
150000001875 compounds Chemical class 0.000 description 18
230000001833 anti-estrogenic effect Effects 0.000 description 17
230000000259 anti-tumor effect Effects 0.000 description 15
230000005764 inhibitory process Effects 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
206010006187 Breast cancer Diseases 0.000 description 13
208000026310 Breast neoplasm Diseases 0.000 description 13
230000003078 antioxidant effect Effects 0.000 description 13
210000002700 urine Anatomy 0.000 description 12
ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 11
108010007622 LDL Lipoproteins Proteins 0.000 description 11
102000007330 LDL Lipoproteins Human genes 0.000 description 11
241001465754 Metazoa Species 0.000 description 11
229940011871 estrogen Drugs 0.000 description 11
239000000262 estrogen Substances 0.000 description 11
VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 10
DWONJCNDULPHLV-HOTGVXAUSA-N Enterodiol Chemical compound C([C@@H](CO)[C@H](CO)CC=1C=C(O)C=CC=1)C1=CC=CC(O)=C1 DWONJCNDULPHLV-HOTGVXAUSA-N 0.000 description 10
AOJXPBNHAJMETF-UHFFFAOYSA-N Enterodiol Natural products OCC(Cc1ccc(O)cc1)C(CO)Cc2ccc(O)cc2 AOJXPBNHAJMETF-UHFFFAOYSA-N 0.000 description 10
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
230000003647 oxidation Effects 0.000 description 10
238000007254 oxidation reaction Methods 0.000 description 10
229960005309 estradiol Drugs 0.000 description 9
235000004426 flaxseed Nutrition 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 8
102000014654 Aromatase Human genes 0.000 description 8
108010078554 Aromatase Proteins 0.000 description 8
201000011510 cancer Diseases 0.000 description 8
238000011161 development Methods 0.000 description 8
230000000694 effects Effects 0.000 description 8
235000013305 food Nutrition 0.000 description 8
230000003859 lipid peroxidation Effects 0.000 description 8
238000005259 measurement Methods 0.000 description 8
239000003963 antioxidant agent Substances 0.000 description 7
235000006708 antioxidants Nutrition 0.000 description 7
239000003886 aromatase inhibitor Substances 0.000 description 7
230000004060 metabolic process Effects 0.000 description 7
SBVBJPHMDABKJV-PGCJWIIOSA-N secoisolariciresinol diglucoside Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)CC=2C=C(OC)C(O)=CC=2)=C1 SBVBJPHMDABKJV-PGCJWIIOSA-N 0.000 description 7
SBVBJPHMDABKJV-UHFFFAOYSA-N secoisolariciresinol diglycoside Natural products C1=C(O)C(OC)=CC(CC(COC2C(C(O)C(O)C(CO)O2)O)C(COC2C(C(O)C(O)C(CO)O2)O)CC=2C=C(OC)C(O)=CC=2)=C1 SBVBJPHMDABKJV-UHFFFAOYSA-N 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
NRAPUSPCLWHFAN-JQFCIGGWSA-N 7-Hydroxyenterolactone Chemical compound C([C@@H]1[C@H](C(OC1)=O)[C@@H](O)C=1C=C(O)C=CC=1)C1=CC=CC(O)=C1 NRAPUSPCLWHFAN-JQFCIGGWSA-N 0.000 description 6
229940122815 Aromatase inhibitor Drugs 0.000 description 6
241000196324 Embryophyta Species 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
241000218657 Picea Species 0.000 description 6
206010060862 Prostate cancer Diseases 0.000 description 6
208000000236 Prostatic Neoplasms Diseases 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
238000011534 incubation Methods 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
239000002207 metabolite Substances 0.000 description 6
238000000034 method Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
235000005911 diet Nutrition 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
238000011835 investigation Methods 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
239000002243 precursor Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
229960003604 testosterone Drugs 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
239000004322 Butylated hydroxytoluene Substances 0.000 description 4
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
206010071289 Lower urinary tract symptoms Diseases 0.000 description 4
102000009151 Luteinizing Hormone Human genes 0.000 description 4
108010073521 Luteinizing Hormone Proteins 0.000 description 4
208000004403 Prostatic Hyperplasia Diseases 0.000 description 4
239000008351 acetate buffer Substances 0.000 description 4
229960005471 androstenedione Drugs 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000037396 body weight Effects 0.000 description 4
235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
229940095259 butylated hydroxytoluene Drugs 0.000 description 4
230000002113 chemopreventative effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
230000012010 growth Effects 0.000 description 4
201000000079 gynecomastia Diseases 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
229940040129 luteinizing hormone Drugs 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000009469 supplementation Effects 0.000 description 4
210000004291 uterus Anatomy 0.000 description 4
MATGKVZWFZHCLI-LSDHHAIUSA-N (-)-matairesinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(OC)C(O)=CC=2)=C1 MATGKVZWFZHCLI-LSDHHAIUSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010009944 Colon cancer Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
235000008124 Picea excelsa Nutrition 0.000 description 3
235000019484 Rapeseed oil Nutrition 0.000 description 3
239000003098 androgen Substances 0.000 description 3
238000005899 aromatization reaction Methods 0.000 description 3
235000019282 butylated hydroxyanisole Nutrition 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
238000001514 detection method Methods 0.000 description 3
230000037213 diet Effects 0.000 description 3
239000000328 estrogen antagonist Substances 0.000 description 3
239000000835 fiber Substances 0.000 description 3
-1 flaxseed lignans Chemical class 0.000 description 3
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
235000000055 matairesinol Nutrition 0.000 description 3
RNXYRAQIZQGUIK-UHFFFAOYSA-N matairesinol Natural products COc1cc(CC2OCC(=O)C2Cc3ccc(O)c(OC)c3)ccc1O RNXYRAQIZQGUIK-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229940097156 peroxyl Drugs 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 3
210000001550 testis Anatomy 0.000 description 3
239000002023 wood Substances 0.000 description 3
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
PUETUDUXMCLALY-HOTGVXAUSA-N (-)-secoisolariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 PUETUDUXMCLALY-HOTGVXAUSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010003591 Ataxia Diseases 0.000 description 2
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 2
239000004255 Butylated hydroxyanisole Substances 0.000 description 2
208000006332 Choriocarcinoma Diseases 0.000 description 2
229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
235000004431 Linum usitatissimum Nutrition 0.000 description 2
240000006240 Linum usitatissimum Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
239000012979 RPMI medium Substances 0.000 description 2
108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 2
102100030758 Sex hormone-binding globulin Human genes 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 2
AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
229940046836 anti-estrogen Drugs 0.000 description 2
235000014590 basal diet Nutrition 0.000 description 2
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
229940043253 butylated hydroxyanisole Drugs 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
235000013399 edible fruits Nutrition 0.000 description 2
229960003399 estrone Drugs 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
SLJZVZKQYSKYNV-ZWKOTPCHSA-N finrozole Chemical compound C([C@H](O)[C@@H](C=1C=CC(=CC=1)C#N)N1N=CN=C1)C1=CC=C(F)C=C1 SLJZVZKQYSKYNV-ZWKOTPCHSA-N 0.000 description 2
LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
229930182480 glucuronide Natural products 0.000 description 2
150000008134 glucuronides Chemical class 0.000 description 2
210000002149 gonad Anatomy 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
125000002887 hydroxy group Chemical class [H]O* 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000001853 liver microsome Anatomy 0.000 description 2
230000029849 luteinization Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
OGFXBIXJCWAUCH-UHFFFAOYSA-N meso-secoisolariciresinol Natural products C1=2C=C(O)C(OC)=CC=2CC(CO)C(CO)C1C1=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
150000002927 oxygen compounds Chemical class 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011002 quantification Methods 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
238000012599 radical scavenging assay Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
235000004239 secoisolariciresinol Nutrition 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
OGFXBIXJCWAUCH-KPHUOKFYSA-N (+)-isolariciresinol Chemical compound C1([C@@H]2[C@@H](CO)[C@H](CO)CC=3C=C(C(=CC=32)O)OC)=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-KPHUOKFYSA-N 0.000 description 1
MHXCIKYXNYCMHY-AUSJPIAWSA-N (+)-lariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@@H]([C@H](OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 MHXCIKYXNYCMHY-AUSJPIAWSA-N 0.000 description 1
HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
FJBQYOWYDLEAKI-UHFFFAOYSA-N (2,3-dimethyl-4-phenylbutyl)benzene Chemical group C=1C=CC=CC=1CC(C)C(C)CC1=CC=CC=C1 FJBQYOWYDLEAKI-UHFFFAOYSA-N 0.000 description 1
GFTUVGXUYWIPMI-BHMOCAHYSA-N (2r,3s,4r,5r,6r)-2-(hydroxymethyl)-6-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methyl]oxane-3,4,5-triol Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)C[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GFTUVGXUYWIPMI-BHMOCAHYSA-N 0.000 description 1
ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
CCTFAOUOYLVUFG-UHFFFAOYSA-N 2-(1-amino-1-imino-2-methylpropan-2-yl)azo-2-methylpropanimidamide Chemical compound NC(=N)C(C)(C)N=NC(C)(C)C(N)=N CCTFAOUOYLVUFG-UHFFFAOYSA-N 0.000 description 1
YHYNYYXJMLXPRQ-NILVNCKXSA-N 4-[hydroxy-[(3r,4r)-4-[hydroxy-(4-hydroxy-3-methoxyphenyl)methyl]oxolan-3-yl]methyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C(O)[C@@H]2[C@H](COC2)C(O)C=2C=C(OC)C(O)=CC=2)=C1 YHYNYYXJMLXPRQ-NILVNCKXSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
241000218631 Coniferophyta Species 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010020853 Hypertonic bladder Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
YVRYZXAHRGGELT-UHFFFAOYSA-N Lariciresinol Natural products C1=C2OCOC2=CC(C2C(C)C3(OC)C=C(CC=C)C(=O)CC3(O2)OC)=C1 YVRYZXAHRGGELT-UHFFFAOYSA-N 0.000 description 1
XCOBLONWWXQEBS-KPKJPENVSA-N N,O-bis(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)O\C(C(F)(F)F)=N\[Si](C)(C)C XCOBLONWWXQEBS-KPKJPENVSA-N 0.000 description 1
206010067572 Oestrogenic effect Diseases 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
241001300028 Pomatias Species 0.000 description 1
GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
CAYMSCGTKZIVTN-TYILLQQXSA-N alpha-Conidendrin Chemical compound C1([C@@H]2[C@@H]3[C@H](C(OC3)=O)CC=3C=C(C(=CC=32)O)OC)=CC=C(O)C(OC)=C1 CAYMSCGTKZIVTN-TYILLQQXSA-N 0.000 description 1
CAYMSCGTKZIVTN-UHFFFAOYSA-N alpha-conidendrin Natural products C1=2C=C(O)C(OC)=CC=2CC(C(OC2)=O)C2C1C1=CC=C(O)C(OC)=C1 CAYMSCGTKZIVTN-UHFFFAOYSA-N 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012159 carrier gas Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
229960000956 coumarin Drugs 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
238000005906 dihydroxylation reaction Methods 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
235000018927 edible plant Nutrition 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000010235 enterohepatic circulation Effects 0.000 description 1
230000008556 epithelial cell proliferation Effects 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
108091009901 estradiol binding proteins Proteins 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
229930003944 flavone Natural products 0.000 description 1
150000002212 flavone derivatives Chemical class 0.000 description 1
235000011949 flavones Nutrition 0.000 description 1
229930003935 flavonoid Natural products 0.000 description 1
235000017173 flavonoids Nutrition 0.000 description 1
150000002215 flavonoids Chemical class 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013373 food additive Nutrition 0.000 description 1
239000002778 food additive Substances 0.000 description 1
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
235000013376 functional food Nutrition 0.000 description 1
229940074391 gallic acid Drugs 0.000 description 1
235000004515 gallic acid Nutrition 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
235000011868 grain product Nutrition 0.000 description 1
244000005709 gut microbiome Species 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
235000009200 high fat diet Nutrition 0.000 description 1
231100000508 hormonal effect Toxicity 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
OEZZQOVAJDAVSJ-UHFFFAOYSA-N isolariciresinol Natural products COc1cc(ccc1O)C1C(CO)C(CO)Cc2cc(O)c(OC)cc12 OEZZQOVAJDAVSJ-UHFFFAOYSA-N 0.000 description 1
230000006651 lactation Effects 0.000 description 1
150000002596 lactones Chemical group 0.000 description 1
235000006826 lariciresinol Nutrition 0.000 description 1
YHYNYYXJMLXPRQ-UHFFFAOYSA-N liovil Natural products C1=C(O)C(OC)=CC(C(O)C2C(COC2)C(O)C=2C=C(OC)C(O)=CC=2)=C1 YHYNYYXJMLXPRQ-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
210000004995 male reproductive system Anatomy 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
235000012459 muffins Nutrition 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
PMOWTIHVNWZYFI-UHFFFAOYSA-N o-Coumaric acid Natural products OC(=O)C=CC1=CC=CC=C1O PMOWTIHVNWZYFI-UHFFFAOYSA-N 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
235000007221 pinoresinol Nutrition 0.000 description 1
OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
150000008442 polyphenolic compounds Chemical class 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
201000005825 prostate adenocarcinoma Diseases 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001373 regressive effect Effects 0.000 description 1
230000002000 scavenging effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000001625 seminal vesicle Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000006884 silylation reaction Methods 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000036325 urinary excretion Effects 0.000 description 1
201000010653 vesiculitis Diseases 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
239000003643 water by type Substances 0.000 description 1
BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Cardiology (AREA)
Nutrition Science (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Botany (AREA)
Heart & Thoracic Surgery (AREA)
Mycology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20014639A 1999-03-30 2001-09-25 Hydroksymatairesinol eller en geometrisk isomer eller en stereoisomer derav for anvendelse for forebygging av en kreftform og farmasoytisk preparat NO330135B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/281,094 US6451849B1 (en)	1999-03-30	1999-03-30	Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol
PCT/FI2000/000181 WO2000059946A1 (en)	1999-03-30	2000-03-09	Hydroxymatairesinol in cancer prevention

Publications (3)

Publication Number	Publication Date
NO20014639D0 NO20014639D0 (no)	2001-09-25
NO20014639L NO20014639L (no)	2001-09-25
NO330135B1 true NO330135B1 (no)	2011-02-21

Family

ID=23075932

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
NO20014639A NO330135B1 (no)	1999-03-30	2001-09-25	Hydroksymatairesinol eller en geometrisk isomer eller en stereoisomer derav for anvendelse for forebygging av en kreftform og farmasoytisk preparat
NO20101067A NO331188B1 (no)	1999-03-30	2010-07-27	Anvendelse av et flytende eller fast materiale anriket med hydroksymatairesinol, matvareprodukt samt fremgangsmate for oking av stabiliteten av et matvareprodukt
NO20101701A NO332110B1 (no)	1999-03-30	2010-12-06	Hydroksymatairesinol for forebygging av ikke-kreft, ostrogenavhengig sykdom
NO20111291A NO332251B1 (no)	1999-03-30	2011-09-23	Hydroksymatairesinol for forebygging av en kardiovaskulaer sykdom

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
NO20101067A NO331188B1 (no)	1999-03-30	2010-07-27	Anvendelse av et flytende eller fast materiale anriket med hydroksymatairesinol, matvareprodukt samt fremgangsmate for oking av stabiliteten av et matvareprodukt
NO20101701A NO332110B1 (no)	1999-03-30	2010-12-06	Hydroksymatairesinol for forebygging av ikke-kreft, ostrogenavhengig sykdom
NO20111291A NO332251B1 (no)	1999-03-30	2011-09-23	Hydroksymatairesinol for forebygging av en kardiovaskulaer sykdom

Country Status (25)

Country	Link
US (2)	US6451849B1 (de)
EP (1)	EP1165537B1 (de)
JP (2)	JP4852685B2 (de)
KR (2)	KR100741724B1 (de)
CN (1)	CN1146553C (de)
AT (1)	ATE231500T1 (de)
AU (1)	AU767691B2 (de)
BG (1)	BG65380B1 (de)
BR (1)	BR0007187A (de)
CA (2)	CA2371839C (de)
CZ (2)	CZ302730B6 (de)
DE (1)	DE60001271T2 (de)
DK (1)	DK1165537T3 (de)
EE (1)	EE200100507A (de)
ES (1)	ES2189738T3 (de)
HK (1)	HK1045992B (de)
HU (1)	HUP0200530A3 (de)
MX (1)	MXPA01009714A (de)
NO (4)	NO330135B1 (de)
NZ (1)	NZ512099A (de)
PL (1)	PL199892B1 (de)
RU (1)	RU2241453C2 (de)
SK (2)	SK287749B6 (de)
WO (1)	WO2000059946A1 (de)
ZA (1)	ZA200104440B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6271257B1 (en) *	2000-04-17	2001-08-07	Hormos Nutraceutical Oy Ltd.	Decreasing the intracellular level of β-catenin by administering hydroxymatairesinol
WO2002034277A1 (en) *	2000-10-23	2002-05-02	Council Of Scientific And Industrial Research	Pharmaceutical composition comprising wikstromol and/or matairesinol, its use as hepatoprotectant and process for their isolation from cedrus deodara
EP1428015A4 (de) *	2001-08-16	2008-09-17	Analiza Inc	Verfahren zur löslichkeitsmessung
DE60235642D1 (de) *	2001-11-12	2010-04-22	Analiza Inc	Charakterisierung von molekülen
FI111638B (fi)	2001-11-23	2003-08-29	Hormos Nutraceutical Oy Ltd	Menetelmä hydroksimatairesinolin tuottamiseksi puusta
US7008666B2 (en) *	2001-11-26	2006-03-07	Hormos Nutraceutical Oy Ltd.	Method of inhibiting overactivity of phagocytes or lymphocytes in an individual
FI114022B (fi)	2002-01-17	2004-07-30	Hormos Nutraceutical Oy Ltd	Menetelmä kasvislignaanien valmistamiseksi ja uusi välituote
US20030144216A1 (en) *	2002-01-25	2003-07-31	Mikko Unkila	Method for prevention of diseases in coeliac patients
US7528166B2 (en) *	2002-02-05	2009-05-05	Hormos Medical Corporation	Lignan derivatives
US7048960B2 (en) *	2002-03-22	2006-05-23	Glenn Roy Pizzey	High lignan flaxseed product and product by process
FI20021184A7 (fi)	2002-06-19	2003-12-20	Hormos Medical Ltd	Lignaanivalmisteita
FI114917B (fi) *	2002-08-29	2005-01-31	Hormos Nutraceutical Oy Ltd	Lignaanikomplekseja
FR2851919A1 (fr) *	2003-03-03	2004-09-10	Lmd	Lignanes utilisables comme inhibiteurs de cathepsines et leurs applications
US8099242B2 (en) *	2003-06-12	2012-01-17	Analiza, Inc.	Systems and methods for characterization of molecules
FI116727B (sv)	2003-11-12	2006-02-15	Arbonova Ab Oy	Ny användning för kvistnötsextrakt
JPWO2005063233A1 (ja) *	2003-12-26	2007-07-19	農工大ティー・エル・オー株式会社	肝癌予防及び治療用組成物
WO2005074905A1 (ja) *	2004-02-03	2005-08-18	Kotosugi Inc.	雲南紅豆杉由来イソタキシレシノールを成分とする骨粗しょう症治療・予防薬
JP2008526819A (ja) *	2005-01-10	2008-07-24	ホルモスメディカルリミテッド	エストロゲン欠乏に関連する症状を予防または改善するための組成物を製造するためのリグナンの使用
US7595078B2 (en) *	2005-03-15	2009-09-29	Glanbia Nutritionals Ireland Limited	Methods of increasing flaxseed hull recovery and resultant flax products
WO2008005043A2 (en)	2005-12-19	2008-01-10	Analiza, Inc.	Systems and methods involving data patterns such as spectral biomarkers
DE102006008772A1 (de) *	2006-02-22	2007-08-23	Beiersdorf Ag	Hydroxymatairesinol gegen trockene Haut
DE102006019044A1 (de) *	2006-04-25	2007-10-31	Merck Patent Gmbh	Antioxidantien
FI20106293A0 (fi)	2010-12-06	2010-12-06	Emilia Peuhu	Uudet farmaseuttiset koostumukset
EP2517574B1 (de)	2011-04-29	2015-11-11	Symrise AG	Bestimmte Vanillyllignane und deren Verwendung als Geschmacksverbesserer
US10613087B2 (en)	2012-08-10	2020-04-07	Analiza, Inc.	Methods and devices for analyzing species to determine diseases
RU2510268C1 (ru) *	2012-11-14	2014-03-27	ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "Медресурс"	Средство для лечения эстрогензависимых опухолей
AU2015261470A1 (en)	2014-05-15	2016-10-27	Linnea S.A.	Composition comprising 7-hydroxymatairesinol
US9678076B2 (en)	2014-06-24	2017-06-13	Analiza, Inc.	Methods and devices for determining a disease state
CZ305794B6 (cs) *	2015-04-20	2016-03-16	Výzkumný ústav potravinářský Praha, v.v.i.	Způsob úpravy dřevních suků s přesně regulovanou strukturou drtě pro výrobu lignanů a zařízení k provádění tohoto způsobu, s využitím v potravinářské výrobě
US9669006B2 (en)	2015-07-28	2017-06-06	U.S. Nutraceuticals, LLC	Composition and method to treat and alleviate symptoms of hot flashes in a female subject
CA3008075A1 (en) *	2015-12-09	2017-06-15	Oy Granula Ab Ltd	The use of a composition for lowering cholesterol level in a mammal, a method for its preparation, a composition and a method for preparing food additive comprising said composition
IT201700050994A1 (it) *	2017-05-11	2018-11-11	Linnea Sa	Uso di una Composizione comprendente 7-Idrossimatairesinolo
CN118511077A (zh)	2021-10-28	2024-08-16	克利夫兰诊断有限公司	用于确定多种类型的癌症的分配系统和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL80351A (en) *	1986-10-17	1991-12-15	Univ Bar Ilan	Food supplements containing water-soluble plant extracts having antioxidant properties
GB8628228D0 (en) *	1986-11-26	1986-12-31	Inst Biolog Morya Dalnevostoch	Composition inhibiting pathological addiction to alcohol
US4808674A (en) *	1987-08-24	1989-02-28	General Electric Company	Aryl ester-grafted polyphenylene ethers and phenylene ether-amide graft copolymers prepared therefrom
DE4317466A1 (de)	1993-05-26	1994-12-01	Degussa	Verbessertes Verfahren zur Bleiche von Holzstoffen
RU2070037C1 (ru) *	1993-08-10	1996-12-10	Покровский Михаил Владимирович	Способ получения композиции, обладающей гепатопротекторной и кардиопротекторной активностью
RU2066195C1 (ru) *	1994-05-11	1996-09-10	Рендюк Тамара Даниловна	Средство для лечения хронического пиелонефрита
US5585504A (en) *	1994-09-16	1996-12-17	Merck & Co., Inc.	Process of making cox-2 inhibitors having a lactone bridge
DE69521525T2 (de)	1995-10-18	2002-04-25	Kanoldt Arzneimittel Gmbh	Lignane, verfahren zu ihrer herstellung, ihre pharmazeutische compositionen und anwendungen
WO1997032593A2 (en)	1996-03-08	1997-09-12	Energiser Plc	Composition containing iso-flavonoids and lignans
US5846944A (en)	1996-04-04	1998-12-08	The University Of Saskatchewan	Purified SDG as an antioxidant
JP2987365B1 (ja) *	1998-10-29	1999-12-06	かどや製油株式会社	抗酸化剤
JPWO2005063233A1 (ja) *	2003-12-26	2007-07-19	農工大ティー・エル・オー株式会社	肝癌予防及び治療用組成物

1999
- 1999-03-30 US US09/281,094 patent/US6451849B1/en not_active Expired - Lifetime
2000
- 2000-03-09 JP JP2000609455A patent/JP4852685B2/ja not_active Expired - Fee Related
- 2000-03-09 MX MXPA01009714A patent/MXPA01009714A/es active IP Right Grant
- 2000-03-09 EE EEP200100507A patent/EE200100507A/xx unknown
- 2000-03-09 CZ CZ20100072A patent/CZ302730B6/cs not_active IP Right Cessation
- 2000-03-09 CA CA2371839A patent/CA2371839C/en not_active Expired - Fee Related
- 2000-03-09 KR KR1020017012487A patent/KR100741724B1/ko not_active Expired - Fee Related
- 2000-03-09 HK HK02107351.6A patent/HK1045992B/zh not_active IP Right Cessation
- 2000-03-09 RU RU2001129166/15A patent/RU2241453C2/ru not_active IP Right Cessation
- 2000-03-09 SK SK5010-2009A patent/SK287749B6/sk not_active IP Right Cessation
- 2000-03-09 AU AU31692/00A patent/AU767691B2/en not_active Ceased
- 2000-03-09 AT AT00909388T patent/ATE231500T1/de active
- 2000-03-09 DK DK00909388T patent/DK1165537T3/da active
- 2000-03-09 BR BR0007187-0A patent/BR0007187A/pt not_active Application Discontinuation
- 2000-03-09 CA CA2650297A patent/CA2650297C/en not_active Expired - Fee Related
- 2000-03-09 CZ CZ20013486A patent/CZ301725B6/cs not_active IP Right Cessation
- 2000-03-09 CN CNB008055424A patent/CN1146553C/zh not_active Expired - Fee Related
- 2000-03-09 KR KR1020077003673A patent/KR100741723B1/ko not_active Expired - Fee Related
- 2000-03-09 HU HU0200530A patent/HUP0200530A3/hu unknown
- 2000-03-09 DE DE60001271T patent/DE60001271T2/de not_active Expired - Lifetime
- 2000-03-09 ES ES00909388T patent/ES2189738T3/es not_active Expired - Lifetime
- 2000-03-09 EP EP00909388A patent/EP1165537B1/de not_active Expired - Lifetime
- 2000-03-09 PL PL350367A patent/PL199892B1/pl unknown
- 2000-03-09 NZ NZ512099A patent/NZ512099A/xx not_active IP Right Cessation
- 2000-03-09 WO PCT/FI2000/000181 patent/WO2000059946A1/en not_active Ceased
- 2000-03-09 SK SK1326-2001A patent/SK287001B6/sk not_active IP Right Cessation
2001
- 2001-04-11 US US09/829,944 patent/US20010016590A1/en not_active Abandoned
- 2001-05-30 ZA ZA200104440A patent/ZA200104440B/en unknown
- 2001-08-30 BG BG105856A patent/BG65380B1/bg unknown
- 2001-09-25 NO NO20014639A patent/NO330135B1/no not_active IP Right Cessation
2010
- 2010-07-27 NO NO20101067A patent/NO331188B1/no not_active IP Right Cessation
- 2010-12-06 NO NO20101701A patent/NO332110B1/no not_active IP Right Cessation
- 2010-12-16 JP JP2010280712A patent/JP2011052024A/ja active Pending
2011
- 2011-09-23 NO NO20111291A patent/NO332251B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1146553C (zh)	2004-04-21
NO20014639D0 (no)	2001-09-25
BG65380B1 (bg)	2008-05-30
CZ20013486A3 (cs)	2002-02-13
CZ302730B6 (cs)	2011-10-05
KR20070027770A (ko)	2007-03-09
NO20101701L (no)	2001-09-25
JP2002541158A (ja)	2002-12-03
JP2011052024A (ja)	2011-03-17
DK1165537T3 (da)	2003-05-12
US6451849B1 (en)	2002-09-17
BG105856A (bg)	2002-04-30
CA2650297C (en)	2012-05-15
NZ512099A (en)	2004-01-30
KR100741724B1 (ko)	2007-07-23
NO20101067L (no)	2001-09-25
DE60001271D1 (de)	2003-02-27
WO2000059946A1 (en)	2000-10-12
RU2241453C2 (ru)	2004-12-10
NO332251B1 (no)	2012-08-06
NO332110B1 (no)	2012-06-25
SK287749B6 (sk)	2011-08-04
EE200100507A (et)	2002-12-16
ZA200104440B (en)	2002-07-30
HK1045992B (zh)	2005-02-25
PL199892B1 (pl)	2008-11-28
CZ301725B6 (cs)	2010-06-02
KR20010108434A (ko)	2001-12-07
EP1165537B1 (de)	2003-01-22
HUP0200530A3 (en)	2002-10-28
CA2650297A1 (en)	2000-10-12
NO20111291L (no)	2001-09-25
PL350367A1 (en)	2002-12-02
HUP0200530A2 (hu)	2002-07-29
SK13262001A3 (sk)	2002-02-05
CA2371839A1 (en)	2000-10-12
JP4852685B2 (ja)	2012-01-11
SK287001B6 (sk)	2009-09-07
NO20014639L (no)	2001-09-25
ATE231500T1 (de)	2003-02-15
AU767691B2 (en)	2003-11-20
US20010016590A1 (en)	2001-08-23
MXPA01009714A (es)	2003-06-24
KR100741723B1 (ko)	2007-07-23
AU3169200A (en)	2000-10-23
HK1045992A1 (en)	2002-12-20
NO331188B1 (no)	2011-10-31
BR0007187A (pt)	2002-02-19
EP1165537A1 (de)	2002-01-02
DE60001271T2 (de)	2003-07-31
CN1345315A (zh)	2002-04-17
WO2000059946A8 (en)	2001-01-25
CA2371839C (en)	2011-10-04
ES2189738T3 (es)	2003-07-16

Legal Events

Date	Code	Title	Description
2019-10-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO330135B1 (no)	2011-02-21	Hydroksymatairesinol eller en geometrisk isomer eller en stereoisomer derav for anvendelse for forebygging av en kreftform og farmasoytisk preparat
US7005447B2 (en)	2006-02-28	Food product comprising hydroxymatairesinol
Fayek et al.	2012	Chemical and biological study of Manilkara zapota (L.) Van Royen leaves (Sapotaceae) cultivated in Egypt
JP4889944B2 (ja)	2012-03-07	アンドロゲンによって仲介される疾患を治療するためのエクオールの使用
Idowu et al.	2016	Isolation and characterization of chemical constituents from Chrysophyllum albidum G. Don-Holl. stem-bark extracts and their antioxidant and antibacterial properties
Kampkötter et al.	2008	Isoflavone daidzein possesses no antioxidant activities in cell-free assays but induces the antioxidant enzyme catalase
Traxler et al.	2021	Specialized plant metabolites from indolic and polyphenolic biosynthetic pathways in Wrightia religiosa (Teijsm. & Binn.) Benth. and Wrightia pubescens R. Br.(Apocynaceae)
El-Ghaly et al.	2016	Bioactive Constituents of Pulicaria jaubertii: A promising Antihypertensive Activity.
Kristanty et al.	2012	Isolation of antioxidant and xanthine oxidase inhibitor from n-butanol extract of andaliman fruit (Zanthoxylum acanthopodium DC.).
Bongmo et al.	2022	Natural Resources for Human Health
Mbwambo	1996	Bioactive constituents from Euphorbia quinquecostata and Mezoneuron cucullatum